Frontiers reaches 6.4 on Journal Impact Factors

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00040

Live-cell mesothelioma biobank to explore mechanisms of tumor progression

 Kathrin Oehl1,  Jelena Kresoja2, Isabelle Opitz3,  Bart Vrugt1, Walter Weder3, Rolf Stahel4, Peter Wild1 and  Emanuela Felley-Bosco2*
  • 1Department of Pathology and Molecular Pathology, UniversitätsSpital Zürich, Switzerland
  • 2University of Zurich, Switzerland
  • 3Division of Thoracic Surgery, UniversitätsSpital Zürich, Switzerland
  • 4Cancer Center Zurich, UniversitätsSpital Zürich, Switzerland

Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples, and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms.
Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naïve patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort.
Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies.

Keywords: Mesothelioma, primary culture, tumor progression, chemoresistance, genetic profiling, mutations, copy number, cisplatin and pemetrexed

Received: 13 Oct 2017; Accepted: 05 Feb 2018.

Edited by:

Marco Lucchi, University of Pisa, Italy

Reviewed by:

Janaki Deepak, University of Maryland, Baltimore, United States
Anca Maria Cimpean, "Victor Babes" University of Medicine and Pharmacy Timisoara, Romania, Romania  

Copyright: © 2018 Oehl, Kresoja, Opitz, Vrugt, Weder, Stahel, Wild and Felley-Bosco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: PhD. Emanuela Felley-Bosco, University of Zurich, Zürich, Switzerland, Emanuela.Felley-Bosco@usz.ch